Focused On-demand Library for Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P61803

UPID:

DAD1_HUMAN

Alternative names:

Defender against cell death 1

Alternative UPACC:

P61803; D3DS25; O08552; O70364; P46966; P46968; Q6FGA3; Q96GB7

Background:

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1, also known as Defender against cell death 1, plays a crucial role in protein N-glycosylation. This process involves the transfer of a specific glycan from dolichol-pyrophosphate to an asparagine residue within nascent polypeptide chains, a fundamental step in protein maturation and function. DAD1 is a vital component of the oligosaccharyl transferase (OST) complex, working in concert with the Sec61 complex to facilitate protein translocation across the endoplasmic reticulum.

Therapeutic significance:

Understanding the role of Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 could open doors to potential therapeutic strategies.